Related Experiment Video
Updated: Mar 29, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Subgroup mixable inference on treatment efficacy in mixture populations, with an application to time-to-event
Ying Ding1, Hui-Min Lin1, Jason C Hsu2,3
1Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, U.S.A.
Abstract:
In tailored drug development, the patient population is thought of as a mixture of two or more subgroups that may derive differential treatment efficacy. To find the right patient population for the drug to target, it is necessary to infer treatment efficacy in subgroups and combinations of subgroups. A fundamental consideration in this inference process is that the logical relationships between treatment efficacy in subgroups and their combinations should be respected (for otherwise the assessment of treatment efficacy may become paradoxical). We show that some commonly used efficacy measures are not suitable for a mixture population. We also show that the current practice of over-simply extending the least squares means concept when estimating the efficacy in a mixture population is inappropriate. Proposing a new principle called subgroup mixable estimation, we establish the logical relationships among parameters that represent efficacy and develop a simultaneous inference procedure to confidently infer efficacy in subgroups and their combinations. Using oncology studies with time-to-event outcomes as an example, we show that the hazard ratio is not suitable for measuring treatment efficacy in a mixture population and provide appropriate efficacy measures with a rigorous inference procedure.
Related Concept Videos
Comparing the Survival Analysis of Two or More Groups
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Kaplan-Meier Approach
Assumptions of Survival Analysis
Hazard Ratio
For example, in a clinical trial...
Analysis of Population Pharmacokinetic Data

